Talphera (TLPH) Registration filing summary

Company overview and business model

• Specialty pharmaceutical company focused on developing and commercializing innovative therapies for medically supervised settings, including acute care and dialysis-related products.

• Product portfolio includes Niyad (regional anticoagulant for dialysis), LTX-608 (nafamostat for IV infusion), and two pre-filled syringe candidates (Fedsyra and phenylephrine).

• Strategy centers on obtaining approval and commercializing Niyad, with plans to expand into additional acute care therapies.

• Incorporated in Delaware, with a history of name changes and principal offices in San Mateo, CA.

Financial performance and metrics

• Raised approximately $4.1 million in gross proceeds from the March 2025 private placement of common stock and pre-funded warrants.

• As of March 16, 2026, 50,049,824 shares of common stock were issued and outstanding; no preferred stock outstanding.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; all proceeds go to selling stockholders.